Innovative Industrial Properties Inc Dossier - Source-backed chat

Innovative Industrial Properties Inc

IIPRNYSE

SectorReal Estate

IndustryREIT - Industrial

Beta (adjusted)1.23

Intrinsic Value $58.42median of 1 methodbased on filings through 30 Jun 2026

Market Price $51.00Price as of 1 Oct 2026

Near fair valueIntrinsic value is 15% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $1.4B

Enterprise Value $1.6B

Shares Outstanding 29.2M diluted

Next Earnings Date2 Nov 2026

Last ex-dividend30 Jun 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Innovative Industrial Properties (IIPR) is navigating a critical transitional phase. While the company has faced headwinds from tenant defaults (including PharmaCann, 4Front, and Gold Flora) that have pressured near-term revenues and AFFO, it is actively stabilizing its portfolio through aggressive re-leasing efforts. Furthermore, IIPR has successfully addressed its near-term debt maturities by raising capital and refinancing, significantly reducing balance sheet risk. The potential rescheduling of cannabis to Schedule III represents a major structural catalyst that could dramatically improve tenant credit quality by eliminating the 280E tax burden. However, until these regulatory reforms materialize and the newly signed leases fully stabilize cash flows, a Hold recommendation is warranted to balance the high dividend yield against ongoing tenant credit risks.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets4 analysts · as of 18 Aug 2026

Low · most bearish analyst$51.00

Mean target$63.25

High · most bullish analyst$90.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$51.0020%

The bear case involves prolonged regulatory delays in cannabis rescheduling, leaving operators exposed to high tax rates and price compression. This leads to further tenant defaults among multi-state and single-state operators, driving down rent collection rates and increasing property vacancies. Re-leasing efforts take longer and cost more than expected, forcing rent concessions. The resulting cash flow compression pressures the dividend coverage ratio, potentially forcing a dividend cut to preserve liquidity.

Base CaseCentral scenario

$63.2550%

Matches the consensus mean

The base case assumes gradual stabilization of the tenant portfolio. IIPR continues to make steady progress re-leasing properties tied to defaulted tenants (such as PharmaCann and 4Front) with transitions completing by late 2026. Refinancing activities, including the issuance of exchangeable senior notes, successfully manage debt maturities. Cannabis rescheduling proceeds slowly, providing long-term credit relief to tenants but not yielding immediate financial impacts. Revenues and AFFO remain relatively flat to modestly up, safely covering the annualized $7.60 dividend.

Bull CaseUpside scenario

$90.0030%

The bull case is driven by rapid federal regulatory reform, specifically the formal rescheduling of cannabis to Schedule III. This change eliminates the IRC Section 280E tax penalty, immediately boosting operator cash flows and credit profiles. Consequently, tenant defaults cease, rent collection rates return to 100%, and IIPR successfully re-leases all vacant properties at favorable rates. Additionally, the company's strategic diversification into life sciences via its IQHQ investment delivers stable, high-yielding non-cannabis cash flows, driving robust AFFO growth and supporting further dividend increases.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

High dividend yield supported by a stable annualized payout of $7.60 per share.
Strong balance sheet with low leverage and proactive management of debt maturities, including the refinancing of senior notes.
Significant upside potential from federal regulatory reforms, particularly Schedule III rescheduling and 280E tax relief for tenants.
Strategic diversification into the resilient life science real estate sector through a major investment in IQHQ.

Key Investment Risks

High concentration of tenant credit risk within the volatile and heavily taxed US cannabis industry.
Risk of further tenant defaults or lease restructurings impacting near-term rental revenues and cash flows.
Potential delays or roadblocks in the federal rescheduling process, prolonging financial pressure on operators.
Exposure to rising interest rates, which can increase refinancing costs and compress REIT valuation multiples.

Thesis Invalidation Triggers

A formal rejection or indefinite postponement of the proposed cannabis rescheduling to Schedule III.
Additional major tenant defaults representing more than 10% of annualized base rent.
A decision by the board to cut the common stock dividend due to cash flow compression.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.